| Literature DB >> 31015674 |
Rajani Adiga1, Mustafa Al-Adhami1,2, Abhay Andar1, Shayan Borhani1,3, Sheniqua Brown1,3, David Burgenson1,3, Merideth A Cooper4, Sevda Deldari1,3, Douglas D Frey1,3, Xudong Ge1,3, Hui Guo1,3, Chandrasekhar Gurramkonda1, Penny Jensen5, Yordan Kostov1,3, William LaCourse6, Yang Liu3, Antonio Moreira1,3, KarunaSri Mupparapu1, Chariz Peñalber-Johnstone1, Manohar Pilli1, Benjamin Punshon-Smith7, Aniruddha Rao1,6, Govind Rao8,9, Priyanka Rauniyar10, Sergei Snovida5, Kanika Taurani1, Dagmawi Tilahun1, Leah Tolosa1,3, Michael Tolosa1, Kevin Tran1, Krishna Vattem5, Sudha Veeraraghavan11,12, Brandon Wagner1, Joshua Wilhide10, David W Wood4, Adil Zuber3.
Abstract
Manufacturing technologies for biologics rely on large, centralized, good-manufacturing-practice (GMP) production facilities and on a cumbersome product-distribution network. Here, we report the development of an automated and portable medicines-on-demand device that enables consistent, small-scale GMP manufacturing of therapeutic-grade biologics on a timescale of hours. The device couples the in vitro translation of target proteins from ribosomal DNA, using extracts from reconstituted lyophilized Chinese hamster ovary cells, with the continuous purification of the proteins. We used the device to reproducibly manufacture His-tagged granulocyte-colony stimulating factor, erythropoietin, glucose-binding protein and diphtheria toxoid DT5. Medicines-on-demand technology may enable the rapid manufacturing of biologics at the point of care.Entities:
Mesh：
Substances：
Year: 2018 PMID： 31015674 DOI： 10.1038/s41551-018-0259-1
Source DB: PubMed Journal: Nat Biomed Eng ISSN： 2157-846X Impact factor: 25.671